

The board of directors (the “Directors”) of Extrawell Pharmaceutical Holdings Limited (the “Company”) announce the unaudited consolidated results of the Company and its subsidiaries (the “Group”) for the six months ended 30 September 2001. A summary extract of this interim financial report is published in a press announcement on 12 November 2001.

**CONDENSED CONSOLIDATED PROFIT AND LOSS ACCOUNT  
(UNAUDITED)**

		<b>For the six months ended 30 September</b>	
		<b>2001</b>	<b>2000</b>
		<b>HK\$'000</b>	<b>HK\$'000</b>
	Notes		
TURNOVER	2	<b>63,670</b>	52,274
Cost of sales		<b>(29,207)</b>	(29,283)
Gross profit		<b>34,463</b>	22,991
Other revenue		<b>4,281</b>	2,448
Selling and distribution expenses		<b>(7,121)</b>	(6,777)
Administrative expenses		<b>(10,393)</b>	(9,412)
PROFIT FROM OPERATING ACTIVITIES	3	<b>21,230</b>	9,250
Finance costs	4	<b>(811)</b>	(890)
PROFIT BEFORE TAX		<b>20,419</b>	8,360
Tax	5	<b>(2,511)</b>	(916)
PROFIT BEFORE MINORITY INTERESTS		<b>17,908</b>	7,444
Minority interests		<b>(1,636)</b>	(1,549)
NET PROFIT FROM ORDINARY ACTIVITIES ATTRIBUTABLE TO SHAREHOLDERS		<b>16,272</b>	5,895
Dividend	6	<b>—</b>	—
EARNINGS PER SHARE	7		
– Basic		<b>HK0.86 cent</b>	HK0.31 cent
– Diluted		<b>N/A</b>	N/A

Other than the net profit from ordinary activities attributable to shareholders, the Group had no recognised gains or losses. Accordingly, a Condensed Consolidated Statement of Recognised Gains and Losses is not presented in the condensed financial statements.